Drugs / UCT-03-008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05103046 | Dec 2021 → Dec 2024 | — | 1200 Pharma, LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCT-03-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05103046 ↗ |
| Action | Inhibit | “Orally available kinase inhibitor” NCT05103046 ↗ |
| Route | Oral | “Orally available kinase inhibitor” NCT05103046 ↗ |